Previous 10 | Next 10 |
iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...
Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany PR Newswire SALT LAKE CITY , Nov. 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, pat...
Coronavirus stock Co-Diagnostics (NASDAQ: CODX) was a standout on Friday as it zoomed well past the gain of the S&P 500 index to book a 7.6% increase on the day. Investors were cheered by a far better-than-expected earnings report published that morning by the testing-pr...
Co-Diagnostics, Inc. (CODX) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Andrew Benson – Head of Investor Relations Dwight Egan – Chief Executive Officer Brian Brown – CFO Conference Call Participants Yi Chen – H.C Unidentifi...
Co-Diagnostics (NASDAQ:CODX) says that it is expecting 2021 revenue to be between $96M and $100M, above the consensus of $95.22M. Shares are up 14% in after-hours trading. In addition, the company is forecasting diluted earnings per share to be between $1.07 to $1.16 range vs. ...
Co-Diagnostics (NASDAQ:CODX): Q3 GAAP EPS of $0.38 beats by $0.17. Revenue of $30.1M (+37.9% Y/Y) beats by $5.78M. Press Release Full Year 2021 Outlook:Co-Diagnostics is offering the following guidance for its full year of 2021: Revenue to be in the range of $96.0 million to $100.0 million vs...
Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38 PR Newswire SALT LAKE CITY , Nov. 11, 2021 ...
Co-Diagnostics (NASDAQ:CODX) is scheduled to announce Q3 earnings results on Thursday, November 11th, after market close. The consensus EPS Estimate is $0.21 (-60.4% Y/Y) and the consensus Revenue Estimate is $24.32M (+11.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revis...
Co-Diagnostics (NASDAQ:CODX) announces that its Logix Smart SARS-CoV-2 2-Gene multiplex test has been approved for use in the United Kingdom. The company launched its Logix Smart ZDC multiplex test at the 64th Annual 2019 Caribbean Public Health Agency (CARPHA) Health Rese...
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom Company's validated test available in the UK following implementation of UKHSA CTDA Regulations PR Newswire SALT LAKE CITY , Nov. 4, 2021 /PRNewswire/ -- ...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...